Calcium antagonists in hypertension

Blood Pressure

Volumn 10, Issue 5-6, 2001, Pages 387-397

  Elliott, William J ^a   Black, Henry R ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALAT CC; AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL T TYPE; CHLORTALIDONE; DILTIAZEM; DIURETIC AGENT; DYNACIRC CR; ENALAPRIL; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICALAN SR; ICISOPTIN SR; ISRADIPINE; LACIDIPINE; LISINOPRIL; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; PENTAERYTHRITYL TETRANITRATE; PERINDOPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG; VERAPAMIL; VERELAN PM; CALCIUM CHANNEL BLOCKING AGENT;

CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; EDEMA; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; CLINICAL TRIAL; ECONOMICS; META ANALYSIS; MORTALITY; TREATMENT OUTCOME;

CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; HUMANS; HYPERTENSION; META-ANALYSIS; TREATMENT OUTCOME;

EID: 0035527583     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753400674     Document Type: Review

References (53)

1. Calcium-antagonist drugs
2. Calcium antagonists and their mode of action: An historical overview
3. Calcium channel blockers: Is it time to split the lump?
4. 2+ channels
5. 2+ channels
6. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
7. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)
8. Retardation of angiographic progression of coronary artery disease by nifedipine
9. Efficacy and safety of calcium channel blockers in heart failure: Focus on recent trials with second-generation dihydropyridines
10. Drug delivery systems for antihypertensive agents
11. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant patients
12. Drug-grapefruit juice interactions
13. Medically-induced gingival hyperplasia
14. Physical Symptoms Distress Index: A sensitive tool to evaluate the impact of pharmacological agents on quality of life
15. The FDA's decisions regarding new indications for approved drugs. Where's the evidence?
16. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?
17. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
18. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes
19. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
20. The risk of myocardial infarction associated with antihypertensive drug therapies
21. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
22. Surgical bleeding: Unexpected effect of a calcium antagonist
23. Do calcium channel blockers increase the risk of cancer?
24. Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia
25. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly
26. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: A 5-year, prospective, randomised, controlled trial
27. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM
28. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
29. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension
30. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
31. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
32. Chinese trial on isolated systolic hypertension in the elderly
33. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
34. J-curve not burned off by HOT Study. Hypertension Optimal Treatment
35. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study
36. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the Int'l Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
37. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study
38. Another scare about antihypertensive therapy
39. Blood-pressure-lowering treatment
40. Blood-pressure-lowering treatment
41. Blood-pressure-lowering treatment
42. Blood-pressure-lowering treatment
43. Blood-pressure-lowering treatment
44. Blood-pressure-lowering treatment
45. Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
46. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments
47. Blood-pressure lowering treatment
48. Selection of antihypertensive therapy for patients with hypertensive renal disease
49. The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
50. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy
51. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
52. Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial